Literature DB >> 16501582

[3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain.

Cristiana Griffante1, Renzo Carletti, Filippo Andreetta, Mauro Corsi.   

Abstract

1 In this study, [(3)H]GR205171 (3(S)-(2-methoxy-5-(5-trifluoromethyltetrazol-1-yl)-phenylmethylamino)-2(S)-phenylpiperidine), a potent and selective NK1 receptor antagonist, was characterised in autoradiographic studies in gerbil brain and in binding experiments on homogenates from gerbil and human brain cortex and striatum. 2 In autoradiographic studies in gerbil brain, highest levels of [(3)H]GR205171 binding sites were observed in caudate putamen, nucleus accumbens, medial and cortical nuclei of the amygdala and intermediate levels were detected in the hypothalamus, basolateral amygdala, septum, and cortex. 3 Saturation experiments in homogenates of brain striatum from gerbil showed that [(3)H]GR205171 binds to a single receptor population with a pK(d) value of 10.8+/-0.2 and a B(max) value of 607+/-40 fmol mg(-1). A lower number of NK1 receptor sites was found in cortex, where a B(max) of 94+/-6 fmol mg(-1) protein was obtained. Saturation experiments performed on homogenates from brain striatum of two human subjects and brain cortex of three human subjects showed that [(3)H]GR205171 binds with pK(d) values not different from gerbil and B(max) values ranging from 318+/-51 to 432+/-27 fmol mg(-1) protein in striatum and from 59+/-1 to 74+/-21 fmol mg(-1) protein in cortex. The natural ligand [(3)H]Substance P (SP) bound with sub-nanomolar affinity to 15 and 6% sites compared to [(3)H]GR205171 in gerbil and human striatum, respectively. 4 In competition binding experiments, GR205171 and the NK1 receptor antagonists aprepitant (MK-869), L-733,060 and NKP-608 bound with similar pK(i) values in gerbil and human striatum, irrespective of the use of [(3)H]GR205171 or [(3)H]SP as radioligand. The following rank order was found in terms of pK(i) values: GR205171>aprepitant> or =L-733,060>NKP-608. In homologous displacement experiments in gerbil and human striatum, SP showed nanomolar affinity, whereas in [(3)H]GR205171 competition experiments SP bound with pIC(50) values in the micromolar range and Hill slopes significantly lower than one. 5 It is concluded that the similarities of [(3)H]GR205171 binding characteristics and pharmacology between gerbil and human in cortex and striatum support the use of gerbil in preclinical models to study the effects of NK1 receptor antagonists in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501582      PMCID: PMC1617048          DOI: 10.1038/sj.bjp.0706697

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach.

Authors:  Stefano Zamuner; Roberto Gomeni; Alan Bye
Journal:  Nucl Med Biol       Date:  2002-01       Impact factor: 2.408

Review 2.  Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.

Authors:  Inga Herpfer; Klaus Lieb
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats.

Authors:  A Vassout; S Veenstra; K Hauser; S Ofner; F Brugger; W Schilling; C Gentsch
Journal:  Regul Pept       Date:  2000-12-22

4.  Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1 ) receptor in assays for antidepressant and anxiolytic drugs.

Authors:  N M Rupniak; E J Carlson; J K Webb; T Harrison; R D Porsolt; S Roux; C de Felipe; S P Hunt; B Oates; A Wheeldon
Journal:  Behav Pharmacol       Date:  2001-11       Impact factor: 2.293

5.  Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils.

Authors:  S Cheeta; S Tucci; J Sandhu; A R Williams; N M Rupniak; S E File
Journal:  Brain Res       Date:  2001-10-12       Impact factor: 3.252

6.  Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain.

Authors:  Michael Rigby; Ruth O'Donnell; Nadia M J Rupniak
Journal:  J Comp Neurol       Date:  2005-10-03       Impact factor: 3.215

7.  Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.

Authors:  Ruth A Duffy; Geoffrey B Varty; Cynthia A Morgan; Jean E Lachowicz
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

8.  The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test.

Authors:  G B Varty; M E Cohen-Williams; J C Hunter
Journal:  Behav Pharmacol       Date:  2003-02       Impact factor: 2.293

9.  The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists.

Authors:  Geoffrey B Varty; Mary E Cohen-Williams; Cynthia A Morgan; Ursula Pylak; Ruth A Duffy; Jean E Lachowicz; Galen J Carey; Vicki L Coffin
Journal:  Neuropsychopharmacology       Date:  2002-09       Impact factor: 7.853

Review 10.  Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.

Authors:  Richard Hargreaves
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

View more
  8 in total

1.  PET imaging of neurokinin-1 receptors with [(18)F]SPA-RQ in human subjects: assessment of reference tissue models and their test-retest reproducibility.

Authors:  Fumihiko Yasuno; Sandra M Sanabria; Donald Burns; Richard J Hargreaves; Subroto Ghose; Masanori Ichise; Frederick T Chin; Cheryl L Morse; Victor W Pike; Robert B Innis
Journal:  Synapse       Date:  2007-04       Impact factor: 2.562

Review 2.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

3.  Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.

Authors:  Padmanabhan Mannangatti; Santhanalakshmi Sundaramurthy; Sammanda Ramamoorthy; Lankupalle D Jayanthi
Journal:  Psychopharmacology (Berl)       Date:  2016-12-24       Impact factor: 4.530

4.  A pharmacokinetic PET study of NK₁ receptor occupancy.

Authors:  Stefano Zamuner; Eugenii A Rabiner; Sofia A Fernandes; Massimo Bani; Roger N Gunn; Roberto Gomeni; Emilangelo Ratti; Vincent J Cunningham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-10-13       Impact factor: 9.236

5.  Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.

Authors:  Scott A Heldt; Michael Davis; Emiliangelo Ratti; Mauro Corsi; David Trist; Kerry J Ressler
Journal:  Behav Pharmacol       Date:  2009-10       Impact factor: 2.293

6.  Association between amygdala neurokinin-1 receptor availability and anxiety-related personality traits.

Authors:  Johanna M Hoppe; Andreas Frick; Fredrik Åhs; Clas Linnman; Lieuwe Appel; My Jonasson; Mark Lubberink; Bengt Långström; Örjan Frans; Lars von Knorring; Mats Fredrikson; Tomas Furmark
Journal:  Transl Psychiatry       Date:  2018-08-28       Impact factor: 6.222

7.  First evaluation of [11C]R116301 as an in vivo tracer of NK1 receptors in man.

Authors:  Saskia P A Wolfensberger; Bart N M van Berckel; Anu J Airaksinen; Kaoru Maruyama; Mark Lubberink; Ronald Boellaard; William D H Carey; Wieb Reddingius; Dick J Veltman; Albert D Windhorst; Josée E Leysen; Adriaan A Lammertsma
Journal:  Mol Imaging Biol       Date:  2009-03-31       Impact factor: 3.488

8.  Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: a positron emission tomography study with [11C]GR205171.

Authors:  A Frick; F Ahs; C Linnman; M Jonasson; L Appel; M Lubberink; B Långström; M Fredrikson; T Furmark
Journal:  Transl Psychiatry       Date:  2015-07-07       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.